Literature DB >> 9684721

Differential effects of bupivacaine on cardiac K channels: role of channel inactivation and subunit composition in drug-channel interaction.

L J Lipka1, M Jiang, G N Tseng.   

Abstract

INTRODUCTION: We examined the effects of a nonspecific ion channel blocker, bupivacaine, on K channels encoded by hERG, rKv1.4, rKv4.3, and hKvLQT1 along with hIsK. Their native counterparts in the heart are important for the function of I(Kr), I(to) and I(Ks) and, thus, play an important role in repolarization. METHODS AND
RESULTS: To elucidate the mechanisms and sites of bupivacaine's actions, we correlated the voltage and time dependencies of drug effects with those of channel gating. We also studied the effects of altering the C-type (hERG) or N-type (rKv1.4) inactivation process or the subunit composition (hKvLQT1 with or without hIsK) on bupivacaine's actions. The results suggest that, except for hKvLQT1 co-expressed with hIsK, bupivacaine binding occurred at depolarized voltages coinciding with channel activation. With hKvLQT1 co-expressed with hIsK, bupivacaine bound preferentially at negative voltages when channels were in the closed state, and unbound at depolarized voltages when channels opened. The C-type inactivation of hERG enhanced, whereas the N-type inactivation of rKv1.4 hindered, bupivacaine's effects.
CONCLUSION: We propose that bupivacaine's actions on these K channels can be described as a nonspecific pore blockade in the inner mouth region. However, the apparent binding affinity and voltage dependence of binding can be differentially influenced by the inactivation processes occurring at two ends of the pore (C-type inactivation at the outer end and N-type inactivation at the inner end), or by the interaction between hIsK and hKvLQT1 subunits.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684721     DOI: 10.1111/j.1540-8167.1998.tb00960.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

1.  Mechanism underlying bupivacaine inhibition of G protein-gated inwardly rectifying K+ channels.

Authors:  W Zhou; C Arrabit; S Choe; P A Slesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block.

Authors:  Teresa González; Cristina Arias; Ricardo Caballero; Ignacio Moreno; Eva Delpón; Juan Tamargo; Carmen Valenzuela
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5).

Authors:  T González; M Longobardo; R Caballero; E Delpón; J V Sinisterra; J Tamargo; C Valenzuela
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Cardiotoxicity with modern local anaesthetics: is there a safer choice?

Authors:  L E Mather; D H Chang
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Bupivacaine effects on hKv1.5 channels are dependent on extracellular pH.

Authors:  M Longobardo; T González; R Caballero; E Delpón; J Tamargo; C Valenzuela
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Bupivacaine blocks N-type inactivating Kv channels in the open state: no allosteric effect on inactivation kinetics.

Authors:  Johanna Nilsson; Michael Madeja; Fredrik Elinder; Peter Arhem
Journal:  Biophys J       Date:  2008-09-12       Impact factor: 4.033

7.  Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.

Authors:  Christopher E Dempsey; Dominic Wright; Charlotte K Colenso; Richard B Sessions; Jules C Hancox
Journal:  J Chem Inf Model       Date:  2014-02-06       Impact factor: 4.956

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.